厄贝沙坦治疗早期糖尿病肾病疗效分析

目的观察厄贝沙坦治疗早期2型糖尿病肾病的临床效果。方法确诊为早期2型DN患者90例，随机分成对照组（45例）和观察组（45例）。对照组予传统常规治疗，控制血糖、血压（降压药排除ACEI及或ARB类）、血脂。观察组在对照组治疗的基础上加用或换用厄贝沙坦控制血压，3月后比较两组血压、血脂、血糖指标、尿微量白蛋白及血清胱抑素c的变化。结果两组在治疗前各项指标无明显差异，经过3个月的治疗，两组的血压，血糖（Glu、2hPG、HbAlC），血脂（HDL—C、TG、LDL—C），U—mAlb，CysC和血压较治疗前均有明显好转，差异有统计学意义（P〈0．01）；观察组的U．mAlb和CysC较对照组改善更明显（P〈0．05）。结论厄贝沙坦治疗早期糖尿病肾病，能有效减少U—mAlb及改善CysC水平，可能对延缓早期糖尿病肾脏病的进展有益。

Irbesartan in treatment of early type 2 diabetic nephropathy

Objective To observe clinical effects of Irbesartan in treatment of early type 2 diabetic nephropathy. Methods Ninety patients with early type 2 diabetic nephropathy were enrolled in the study, including 45 patients treated with conventional medication （control group ） and another 45 patients treated with irbesartan （observation group）. The blood sugar, renal function index, urine albumin, plasma cystatin C were measured 3 months after treatment. Results Compare to control group, observation group had better clinical effect and laboratory results; there were significant differences in blood sugar （ Glu, 2hPG and HbA1 c ） and blood lipid （ HDL-C, TG, LDL-C ） levels, blood pressure control and kidney functions （U-mAlb and cystatin C） between two groups （all P 〈 0.05 ）. Conclusion Irbesartan has better clinical effect than conventional medication in treatment of early type 2 diabetic nephropathy.